Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-91657-7, published online 08 June 2021
The original version of this Article contained errors in Table 4, where the P value was omitted and the “Adjusted HR (95% CI)a” value for “ECOG PS” was incorrectly assigned. The correct and incorrect values appear below.
Incorrect:
Characteristics | HR (95% CI)a | P value | Adjusted HR (95% CI)a | P value |
|---|---|---|---|---|
Smoking status | ||||
NS | Reference | 0.51 (0.29–0.90) | ||
C/FS | 1.59 (0.95–2.65) | 0.079 | ||
ECOG PS | ||||
2–4 | Reference | |||
0–1 | 0.52 (0.30–0.90) | 0.019 | ||
Correct:
Characteristics | HR (95% CI)a | P value | Adjusted HR (95% CI)a | P value |
|---|---|---|---|---|
Smoking status | ||||
NS | Reference | |||
C/FS | 1.59 (0.95–2.65) | 0.079 | ||
ECOG PS | ||||
2–4 | Reference | |||
0–1 | 0.52 (0.30–0.90) | 0.019 | 0.51 (0.29–0.90) | 0.020 |
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Huang, YH., Tseng, JS., Hsu, KH. et al. Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Sci Rep 11, 17646 (2021). https://doi.org/10.1038/s41598-021-97248-w
Published:
Version of record:
DOI: https://doi.org/10.1038/s41598-021-97248-w
This article is cited by
-
‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma
Journal of Cancer Research and Clinical Oncology (2024)
